Buy side vs sell side

The program's goal was never "get a finance job". It was understand businesses, a capability that is valuable whether you ever manage a rupee or dollar of anyone else's money (it makes you a better operator, board member, entrepreneur, and steward of your own savings). But some learners will want to turn the skill into a profession, so here is an honest map. This is orientation, not career counseling, and none of it is a recommendation.

The four paths (with their real trade-offs).

Is the buy side or the sell side better?

There is no "best" path. They suit different temperaments, capital positions, and appetites for client-facing work versus solitary analysis. Many great investors moved between them (sell-side → buy-side is common; buy-side → independent is the classic later move). The skill you built transfers to all four; what differs is the packaging and the clientele. If any of the first three is where you are heading, the entry point is a two-minute spoken pitch across a table, and M8.05's two-minute pitch section turns your one-page memo into exactly that, with the six questions that follow and the rubric they are scored on.

The table above describes what a seat is for. What follows is what the seat actually contains, because the difference between the two is where most career surprises live, and because every artefact below is one you have already built under a different name.

What does a sell-side analyst do?

Sell side. The day starts before the open with the morning meeting. Analysts present what changed overnight on their names, in about ninety seconds each, and the sales force carries it to clients through the day. The product of that meeting is not a note; it is a sentence a salesperson can repeat down a phone, which is why the eight-line teardown output of M8.02 is the closest thing in this program to a morning-meeting call. Written output then splits in two. An initiation is the full thesis on a company you have not covered before, forty to a hundred pages, launched with a rating and a target price, and it is the analyst's franchise claim on the stock; it is M10.03's longer research report with a cover on it. An update note is one to four pages, written in a few hours, triggered by an event: results, a guidance change, a regulatory shift, a large contract. Update notes are most of the output and nearly all of the reading.

The rating scale looks simpler than it is. Buy, hold and sell, or overweight, neutral and underweight, are defined relative to a benchmark over a stated horizon, usually twelve months, with a published return band attached to each. So a "hold" is not a view that the company is mediocre; it is a claim that the stock will do roughly what the index does over a year. The target price is a twelve-month fair value with a disclosed methodology, and it obliges the analyst to act when the price reaches it, either by raising the target with a reason or by cutting the rating. Ratings distributions across the industry skew heavily toward buy, for structural reasons that include corporate access and banking relationships, and reading a note well starts with knowing that the scale is not symmetric in practice.

Three constraints shape the rest of the seat. Blackout and quiet periods stop research from publishing on an issuer while the firm is engaged on a transaction involving it, and research sits behind an information barrier from banking; an analyst who goes quiet on a covered name has told you something without telling you anything. Corporate access, meaning arranging management meetings, site visits and conferences for clients, is a large part of what the buy side values and the sharpest conflict on the desk, because access is granted by the issuer whose stock you rate. And the answer to who the client is settles most of the rest: the client is the institutional investor who votes in the broker review that sets your firm's share of their commission budget. Not the issuer, not the retail reader. The analyst is paid for coverage, availability and access as much as for being right, which is the honest trade-off the table above names.

What does a buy-side analyst do?

Buy side. There is no morning meeting to feed and no publication schedule, and the constraint moves from output to decision. The idea pipeline runs from screens, sell-side work, conferences, the network and your own watchlist into a funnel: a one-page note to decide whether the idea deserves a workup, a full workup to decide whether it deserves a position, and an investment-committee memo to get the position approved. That memo is the six-part one-page thesis of M8.04 and M10.03, with two additions the committee will not proceed without: a proposed size with its reasoning, and pre-committed sell criteria (M9.01 and M9.03). Position-sizing conversations with the portfolio manager and the risk function are the part nobody warns you about, and they are not about your target price. They are about your downside floor, whether it is real, and what else in the book is correlated with this idea, which is M9.01's hidden correlation question asked out loud by someone senior.

Then the review cadence, which is the buy side's version of a publication schedule. Every holding is re-underwritten on a fixed rhythm, usually each results season, against the thesis as written on the day it was bought: what has to go right, what has happened, whether any pillar has broken. A thesis-drift check catches the slow substitution of a new reason for owning something in place of the reason you bought it, which is the most common and least visible failure in a long-only book. The other half of the cadence is the kill review, a scheduled look at the ideas you passed on, because a research process that never revisits its rejections learns only from the mistakes it can see.

The buy side's answer to "who is the client" is different in a way that changes the work rather than just the reporting line. Your client is the end investor whose money is in the fund, represented by a mandate: a stated objective, a benchmark, a set of constraints on what you may own and how much of it, and a fee. That mandate is the reason a good idea can be unbuyable. A small-cap name that would take four weeks to accumulate is not an idea for a fund whose liquidity terms promise weekly redemption, however right the analysis is, and a position that breaches a stated sector limit is not a position at all. So a buy-side analyst learns to run a feasibility check before the work rather than after it, asking what size this idea could ever be and whether the mandate permits it, and the ideas that fail that check are dropped early rather than researched and mourned. That check is the professional version of M9.02's caps, and it is why the phrase "great business, wrong fund" is heard more often than beginners expect.

Two differences in the seat itself are worth naming, because they surprise people who move across. The buy-side analyst covers far more names far less deeply than a sell-side counterpart, often forty or sixty rather than fifteen, and is expected to be fluent on all of them and expert on the eight that matter to the book this quarter. And the buy-side analyst's written output is read by three or four people who will argue with it, rather than by three hundred who will skim it, which changes everything about how it is written. A sell-side note must survive being skimmed; an investment-committee memo must survive being attacked. M10.03's two audience treatments, the portfolio manager and the committee, are exactly those two readers.

What is it like to work in either seat?

The mapping between what you have built and what each seat wants is close to exact, and it is worth memorising. Your eight-line teardown output is the morning-meeting call. Your one-page memo is the investment-committee memo, once you add the size and the sell criteria. Your longer report is the initiation. Your update note is what a results print produces on either side of the street. Your decision journal is the review cadence, and your public dated record from building a public track record is the track record that the final competency audit grades. You have been building professional artefacts for sixty-odd weeks under other names, which is why the transition, when people make it, is usually a transition in tempo rather than in skill.

That tempo is the last thing to describe, because it is the part no syllabus contains. The shape of a working day is similar on both sides and it repeats every day the market is open. Pre-open is forty minutes. You read the overnight moves in the markets that lead yours, the exchange filings and wire feed on your covered names, and anything a peer, a supplier or a customer said while you were asleep. You finish with one prepared sentence on each name, in case you are asked, because you will be.

Results-season triage is the skill that separates a calm quarter from a lost one. Forty companies report inside three weeks, you cannot read forty results properly, and pretending otherwise is how analysts end a season having read everything and understood nothing. Triage by one rule: does this print plausibly change a number in my model, or does it merely confirm one? A confirmation gets twenty minutes and a line in the log. A potential change gets the full read, the transcript and the call, and it gets them today.

The update note is written the same day, in about ninety minutes, in a fixed four-part shape: what changed, what it does to the numbers, whether the thesis moves, and what we therefore do. The fourth part is the one juniors omit and the one readers open the note for. The model refresh follows, and its discipline is unglamorous. Actuals go into the actuals column, the forecast rolls forward a period, and every check row is confirmed before a single output is quoted to anyone. Then the call, either the company's results call or a scheduled management meeting, where you bring two prepared questions rather than eight. Two answered properly beat eight asked in a queue, and the second question is usually the one that gets the answer.

After the close there is one more habit worth copying, and it takes ten minutes. Write down what you learned today that would change a number, and what you were asked that you could not answer. The first line feeds the model; the second becomes tomorrow's reading list and, over a year, the honest map of where your coverage is thin.

Nothing in that day is new to you. What is new is the cadence, and the cadence is the point: a professional analyst's day is scheduled around the market's calendar rather than around the work, and the process you built in Phase 8 exists so that a compressed day still produces an honest answer.

What does it take to go professional?

What a track record must show to be credible. Every professional path except "sell-side coverage" is ultimately gated on a track record, and a credible one has specific properties, which is exactly why the public dated record, started years earlier, is the asset that unlocks this door:

• Length through a full cycle. A record that has not lived through a real drawdown proves nothing about risk-taking; credible records span at least one full market cycle (a bull and a bear), so 5+ years is the practical floor.
• Process visible, not just outcomes. The dated theses, the reasoning, the sell decisions, the mistakes owned: a record that shows how you decided is worth far more than a return number, because returns over short periods are mostly luck (working-agreement 8). This is why you leave the losers in the record, annotated.
• Honest, comparable, and unedited. Returns stated against the right benchmark, net of costs, with no cherry-picking and no back-filling; the misses left standing. In a professional setting this becomes audited (GIPS-compliant composites in the institutional world), but the habit starts with your unedited public log.
• Attributable to skill, not to one bet or one regime. A record built on a single lucky position, or that only works in one market regime, is not a track record — it is an anecdote. Breadth and consistency of process across names and conditions is the signal.

The ethics of managing other people's money. The moment you manage money that is not yours, everything changes, because you now hold a fiduciary duty, a legal and moral obligation to put the client's interest strictly ahead of your own. This is the ethics thread of the whole program (Section 8.1) made concrete, and the core obligations are not optional niceties:

• Fiduciary duty and the client's interest first. No self-dealing, no front-running your clients, no putting them in products because they pay you more. The client's interest is the only interest that governs the decision.
• Suitability and honesty about risk. You match the strategy to the client's actual risk tolerance and horizon, and you are honest, in advance and in writing, that markets are uncertain, valuation is a range, past performance does not guarantee future results, and loss is possible (working-agreements 9 and the guardrails of Section 11.3). Never sell certainty you do not have.
• Honest, timely, comparable reporting. You report performance against the right benchmark, net of fees, without hiding the bad quarters: the same unedited honesty as the public record, now owed as a duty.
• Conflicts disclosed, competence bounded. You disclose every conflict of interest, and you do not manage money in strategies or assets outside your genuine competence. And you operate inside the regulatory framework: SEBI (RIA, PMS, and AIF regulations) in India, the SEC/Advisers Act and state rules in the US. Those rules exist precisely to enforce these duties.

The one-line version, which is also just good analysis applied to yourself: manage other people's money only when you can honestly say your process is real, your track record is honest, your competence covers what you are doing, and their interest genuinely comes first. If any of those is not yet true, the ethical and the practical answer are the same: keep building, on your own capital and your own record, until they are.